The PST-001 molecule was designed to be orally active and to penetrate the blood-brain barrier, hence, to be an effective tool compound for investigating the effects of DYRK1A inhibition in vivo. A concentration of 100 mg PST-001/kg food was verified to give a therapeutic level of the drug in the brain of Ts65 Dn DS model mice suppressing their associative memory deficits (Stensen et al., 2021a). This evidence concerns the gene DYRK1A and Dravet syndrome.